# Takeda Pharmaceutical Co Ltd: Form 20-F for the period ended Mar 31, 2021

- Company: [Takeda Pharmaceutical Co Ltd](/companies/tak.md) (CIK 1395064)
- Form: 20-F
- Filed: 2021-06-29
- Accepted by EDGAR: Jun 29, 2021, 06:06 ET
- Period: 2021-03-31
- Accession: 0001395064-21-000140
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2020-04-01 to 2021-03-31 | JPY 3.20tn | ifrs-full:Revenue |
| Cost of revenue | 12 months, 2020-04-01 to 2021-03-31 | JPY 994.31bn | ifrs-full:CostOfSales |
| Operating income | 12 months, 2020-04-01 to 2021-03-31 | JPY 509.27bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months, 2020-04-01 to 2021-03-31 | −JPY 9.94bn | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months, 2020-04-01 to 2021-03-31 | JPY 376.00bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months, 2020-04-01 to 2021-03-31 | JPY 238.96 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2020-04-01 to 2021-03-31 | JPY 240.72 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2020-04-01 to 2021-03-31 | JPY 1.01tn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2020-04-01 to 2021-03-31 | JPY 111.21bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2021-03-31 | JPY 966.22bn | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2021-03-31 | JPY 2.71tn | ifrs-full:CurrentAssets |
| Total assets | at 2021-03-31 | JPY 12.91tn | ifrs-full:Assets |
| Current liabilities | at 2021-03-31 | JPY 1.77tn | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2021-03-31 | JPY 7.74tn | ifrs-full:Liabilities |
| Shareholders' equity | at 2021-03-31 | JPY 5.17tn | ifrs-full:EquityAttributableToOwnersOfParent |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1395064/000139506421000140/tak-20210331.htm

Filed Jun 29, 2021.
Source: SEC EDGAR, the filing index for accession 0001395064-21-000140. Last ingested by Listed: Nov 5, 2026, 16:17 ET. No prices; not investment advice.
